HIGHLIGHTS
- who: SARS CoV- and colleagues from the Department of Paediatrics, University of, UK have published the article: Clinical and Experimental Immunology 280-287 Persistence of the immune_response after two doses of ChAdOx1 nCov-19 (AZD1222): year of follow-up of two randomized controlled trials, in the Journal: (JOURNAL)
- what: The authors report on maintenance of immune responses during the year following a two-dose schedule of ChAdOx1 nCoV-19/AZD1222 in the absence of infection and also explore the decay of antibody after infection. Control group participants were not included in the analysis which is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.